Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.69 |
| ▸ | CCR5 | P51681 | 3/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.61 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.53 |
| ▸ | TACR2 | P21452 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MTR | Q99707 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858744 | 0.89 | DRD2 (0.68) | DRD2SLC6A4CCR5CYP2D6TACR2 | |
| SCHEMBL904830 | 0.85 | DRD2 (0.60) | DRD2SLC6A4CCR5CYP2D6TACR2 | |
| SCHEMBL5858604 | 0.84 | CCR5 (0.50) | DRD2SLC6A4CCR5CYP2D6KCNA3 | |
| SCHEMBL5860246 | 0.84 | CCR5 (0.53) | DRD2SLC6A4CCR5CYP2D6KCNA3 | |
| SCHEMBL5858734 | 0.83 | CCR5 (0.52) | DRD2SLC6A4CCR5CYP2D6TACR2 | |
| SCHEMBL6778397 | 0.80 | DRD2 (0.50) | DRD2SLC6A4CCR5CYP2D6TACR2 | |
| SCHEMBL3132276 | 0.79 | DRD2 (0.67) | DRD2SLC6A4OPRL1OPRM1KMT2A | |
| Hydrochloric Acid SCHEMBL6777403 | 0.79 | TACR2 (0.56) | DRD2SLC6A4CCR5CYP2D6TACR2 | |
| SCHEMBL5857960 | 0.78 | DRD2 (0.54) | DRD2SLC6A4CCR5CYP2D6TACR2 | |
| SCHEMBL6778865 | 0.78 | TACR2 (0.55) | DRD2SLC6A4CCR5TACR2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989393-B2 | Ccr5 modulators benzimidazoles or benzotriazoles | ASTRAZENECA AB (SE) | 2006-01-24 | — | — | US | disclosed |
| US-20030119869-A1 | Ccr5 modulators benzimidazoles or benzotriazoles | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | disclosed |
| EP-1265870-A1 | NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES | AstraZeneca AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001066525-A1 | NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119869-A1 | Ccr5 modulators benzimidazoles or benzotriazoles | CCR5, CCR2, CXCR4 | DRD2 1216/4885SLC6A4 696/4885CCR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.